summari host investor call provid updat
busi overal heard strateg
chang busi maintain focu six key
therapeut area remain agnost sourc innov
 pursu intern busi develop addit
continu see global brand pharmaceut market
grow expect pharma busi grow
market period provid
guidanc view manag tone confid busi
outlook driven strong in-market portfolio late-stag
consensu estim pharma growth impli
growth may prove conserv
atln pharma growth in-lin market
slightli estim believ growth target
reason given product portfolio pipelin busi
develop activ even face drug price pressur
competit headwind rais price target
base ep
still expect pharma busi outgrow broader
pharma market similar may pharma day outlook
continu expect global brand pharmaceut market
grow compound-annual-growth-rate compani expect pharma
busi outpac overal market period
pharma deliv oper growth twice
market math current consensu impli
compound-annual-growth-rate pharma pro forma atln in-lin
market estim pro forma compound-annual-growth-rate
higher growth forecast like reflect part higher sale
sever key product notabl
prezista/prezcobix invega sustenna/trinza darzalex figur
prezista author gener deal expect
keep gener market jnj pharma day
compani estim invega sustenna/trinza could
brand sale forecast still
manag expect assum gener competit
time due drug rel complex manufactur
process darzalex view drug move front-lin
use non-transpl transplant-elig patient well
new formulations/dos help drive continu
strong growth momentum next year
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
continu previou page
consensu forecast appear somewhat conserv near/medium-term look near-
term estim pharma sale growth estim consensu growth
figur consensu forecast repres deceler due
part tougher comp assum growth consum medic devic similar
impli pharma growth achiev full year overal organ sale growth
guidanc figur howev expect growth acceler non-pharma
busi suggest impli pharma growth probabl somewhat
look ahead consensu forecast pharma impli growth mark
slowdown estim possibl even impli growth estim
modest deceler ex-fx pharma sale growth figur give
guidanc manag commentari tone call suggest confid pharma
drug price pressur expect continu concern drug price
reform lack specif help determin time potenti impact accord
compani believ howev chang need implement gradual
addit anticip continu brand drug price come year manag believ
compani well posit continu grow environ jnj net price fell
across pharma portfolio modestli exclud remicad
remicad perform better anticip despit increas biosimilar competit jnj us
remicad sale held better expect manag attribut strength lack
interchang biosimilar mean physician/pati prefer drive prescript
compani also view remicad larg number approv indic competit advantag vs
biosimilar competit us remicad sale fell yr/yr assum similar rate declin
expect biosimilar remicad remain growth headwind estim continu
sale declin high-teen
zytiga continu grow well expect decis us patent case next month global
zytiga sale grew ex-fx includ us growth nearli growth acceler
franchis driven approv metastat high-risk castration-sensit prostat cancer base
latitud studi manag note zytiga sale ou data exclus
europ run septemb us manag note patent trial complet
post-trial brief schedul patent rule expect time thereaft
continu express confid ip continu assum gener zytiga competit would
start follow expir stay late octob past manag
express confid guidanc absorb impact gener zytiga follow
month stay said see us zytiga becom growth headwind assum gener
entri current model us zytiga sale fall
darzalex expect move front-lin treatment expect present data phase
maia studi front-lin multipl myeloma although top-lin result interim analysi
still expect end event driven studi precis time hard pinpoint
partner genmab hold investor event would expect compani give
updat maia continu expect approv base maia help drive darzalex
adopt first-lin mm us cassiopeia front-lin mm transplant-elig patient also
expect file approv split-dos administr like help
reduc physician capac bottleneck continu view subq formul anoth
longer growth driver darzalex anticip file expect reduc infus time
sever hour minut
esketamin opportun remain signific commerci launch strategi develop
file esketamin treatment-resist depress trd septemb expect eu submiss
octob suggest approv possibl manag estim depress affect
peopl global one-third respond treatment may benefit
esketamin market opportun signific given lack option trd uncertain
remain regard jnj launch plan given drug like administ physician
supervis patient may need observ coupl hour post-dos discuss
fda factor reflect drug label compani expect file esketamin
suicid risk
figur estim vs consensu pharmaceut product
note bold product denot sale estim differ
figur impli yr/yr revenu growth
compani report factset secur llc estimateswf vs consensu neg consensu higher pharma organ actual medic technolog
price target
price target impli cash ep base sum-of-the-
part analysi risk includ delay pipelin product unexpect delay deal integr
unexpect deterior industri
expect overal growth improv multipl tailwind recent acquisit start
contribut organ
johnson johnson world comprehens broadli base healthcar compani
consum pharmaceut medic devic market medic devic segment consist primarili
product cardiovascular orthoped surgic vision compani report sale
year-over-year organ basi
